Events

Trending on OncLive

Phase 3 VERSATILE-003 Trial of PDS0101 in HNSCC Is Discontinued

T-DXd Plus Pertuzumab Is Approved in China for First-Line HER2+ Metastatic Breast Cancer

CD24 Expression Confers Resistance to Anti–PD-1 Therapy in NSCLC, RET-TKI Dose Reductions Do Not Compromise Outcomes in RET+ Disease

Intranasal NEO100 Meets Primary End Point in Recurrent IDH1-Mutant High-Grade Glioma

Dr Silverstein on the Efficacy of Abemaciclib and Hormonal Therapy in Recurrent Ovarian and Endometrial Cancer